CanFite Biopharma (CANF)
(Delayed Data from AMEX)
$1.98 USD
+0.06 (3.13%)
Updated Apr 26, 2024 03:49 PM ET
After-Market: $1.96 -0.02 (-1.01%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CANF 1.98 +0.06(3.13%)
Will CANF be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CANF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CANF
Can-Fite (CANF) Up on Liver Cancer Study Update of Namodenoson
Can-Fite Biopharma Ltd (CANF) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
CANF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Best Momentum Stocks to Buy for October 27th
New Strong Buy Stocks for October 27th
Can-Fite (CANF) Up on Namodenoson Progress in Pancreatic Cancer
Other News for CANF
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal
Can-Fite Reports Breakthrough in Liver Cancer Treatment
Can-Fite BioPharma publishes article relating to namodenoson
Can-Fite’s Namodenoson Shows Promise for Liver Cancer